TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34383682

Group type: EXPERIMENTAL
Intervention: Wearable devices (Garmin vivofit for activity monitoring, Philips Actiwatch for sleep monitoring) and smartphones for patient-reported outcomes.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weekly patient-reported outcomes using Brief Psychiatric Rating Scale, Calgary Depression Scale, and Positive and Negative Syndrome Scale.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Elastic net model using sleep and activity features from wearable devices.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall data coverage and compliance with devices.
Number of subjects: 40
Study: 34383774

Group type: EXPERIMENTAL
Intervention: STANDARD G6PD Test (SD Biosensor)
Number of subjects: 1736
Study: 34383875

Group type: EXPERIMENTAL
Intervention: Device ON
Number of subjects: 4

Group type: COMPARATOR
Intervention: Device OFF
Number of subjects: 4
Study: 34383902

Group type: EXPERIMENTAL
Intervention: Heterologous ChAdOx1-S/BNT162b2 Vaccination
Number of subjects: 0
Study: 34384049

Group type: EXPERIMENTAL
Intervention: Supportive services (exercise classes) in retirement communities
Number of subjects: 23

Group type: COMPARATOR
Intervention: No supportive services (exercise classes) in retirement communities
Number of subjects: 23
Study: 34384079

Group type: EXPERIMENTAL
Intervention: 2 consecutive intracavernous injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 22
Study: 34384145

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1958
Study: 34384227

Group type: EXPERIMENTAL
Intervention: Multimodal Treatment Study of ADHD (MTA)
Number of subjects: 558
Study: 34384384

Group type: EXPERIMENTAL
Intervention: Standardized neurological examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry (age ≥ 5 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires (patient report and/or parent proxy; age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle ultrasound including diaphragm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (spirometry, maximal inspiratory and expiratory pressure, sniff nasal inspiratory pressure; age ≥ 5 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometry for 8 days (age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac evaluation (electrocardiogram, echocardiography; age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spine X-ray (age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA-scan; age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full body magnetic resonance imaging (MRI; age ≥ 10 years)
Number of subjects: 0
Study: 34384460

Group type: EXPERIMENTAL
Intervention: Elevated suPAR above 3 ng/ml
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Elevated suPAR above 9 ng/ml
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 414
Study: 34384490

Group type: EXPERIMENTAL
Intervention: Baseline procedures including neurological and neuropsychological examinations; tau and amyloid positron emission tomography; magnetic resonance imaging and spectroscopy; lumbar puncture; blood and saliva collection; standardized self-report measures of neuropsychiatric, cognitive, and daily functioning.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Remote, 4-year follow-up evaluations including telephone-, online-, and videoconference-based cognitive, neuropsychiatric, and neurologic examinations, as well as in-home blood draw.
Number of subjects: 240
Study: 34384695

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR) 28.5 Gy in 3 fractions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MRI %VR
Number of subjects: 19
Study: 34384709

Group type: EXPERIMENTAL
Intervention: MS4A family members as candidate biomarkers and therapeutic targets
Number of subjects: 0
Study: 34384766

Group type: EXPERIMENTAL
Intervention: Functional clusters
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Disease clusters
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Charlson score
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 1967
Study: 34385099

Group type: EXPERIMENTAL
Intervention: COPD screening intervention involving questionnaires, spirometry (COPD6™), and counselling
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Counselling including smoking cessation and chest physician referral
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Counselling including smoking cessation
Number of subjects: 157
Study: 34385234

Group type: EXPERIMENTAL
Intervention: Extubation Advisor (EA) clinical decision support tool
Number of subjects: 117
Study: 34385256

Group type: EXPERIMENTAL
Intervention: Active commuting (walking or cycling)
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Moderate or vigorous leisure-time physical activity (LTPA)
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Active commuting among different employment statuses
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Active commuting and weight status
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA) and age
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA) and gender
Number of subjects: 2815
Study: 34385263

Group type: EXPERIMENTAL
Intervention: Single blood eosinophil count measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two blood eosinophil count measurements
Number of subjects: 0
Study: 34385343

Group type: EXPERIMENTAL
Intervention: DARPin G3 (designed ankyrin repeat proteins)
Number of subjects: 0
Study: 34385584

Group type: EXPERIMENTAL
Intervention: ZEN-3694 combined with CDK4/6 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZEN-3694 treatment
Number of subjects: 0
Study: 34385593

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 16
Study: 34385708

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes (TILs) administered with nivolumab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Safety endpoint
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TIL treatment
Number of subjects: 20
Study: 34385840

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) angioplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both DCB angioplasty and PTA
Number of subjects: 200
Study: 34385972

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34386129

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy defibrillator (CRT-D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondevice (ND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HF pacing (PA; Pacemaker and cardiac resynchronization pacemaker)
Number of subjects: 0
Study: 34386535

Group type: EXPERIMENTAL
Intervention: BESMILE-HF Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34386974

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: Thrombopoietin-receptor agonists (TPO-RAs)
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: History of VT
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: History of cancer
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 10039

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 10039
Study: 34387097

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1680

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: TAVR with low flow (LF)
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: SAVR with low flow (LF) and low ejection fraction
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Normal flow
Number of subjects: 1680
Study: 34387119

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy, 2 times a week for 6 weeks (total of 12 treatments)
Number of subjects: 12
Study: 34387310

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 polymerase chain reaction, immunoglobulin G (IgG) testing for 6 months
Number of subjects: 831

Group type: COMPARATOR
Intervention: Healthcare workers (n = 548)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: IgG antibodies detection
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: IgG trajectories
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Persistent IgG responses
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Dyspnea and neurologic changes
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Prolonged symptoms
Number of subjects: 831
Study: 34387570

Group type: COMPARATOR
Intervention: Nonoperative treatment (bedside irrigation, primary closure, antibiotics, discharge with follow-up)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Operative treatment (surgical debridement, irrigation, and closure)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 189
Study: 34387648

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (2 doses, 21 days apart)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (in patients with B-NHL)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (in patients with i-B-NHL vs a-B-NHL)
Number of subjects: 149
Study: 34387673

Group type: EXPERIMENTAL
Intervention: Chronic venous insufficiency (CVI)
Number of subjects: 12423

Group type: EXPERIMENTAL
Intervention: CVI
Number of subjects: 12423
Study: 34387679

Group type: EXPERIMENTAL
Intervention: Cannabidiol, 300 mg (150 mg twice per day) plus standard care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 120
Study: 34387718

Group type: EXPERIMENTAL
Intervention: Patlak analysis
Number of subjects: 8
Study: 34388020

Group type: EXPERIMENTAL
Intervention: VenDd (venetoclax with daratumumab and dexamethasone)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VenDVd (venetoclax with daratumumab, dexamethasone, and bortezomib)
Number of subjects: 48
Study: 34388205

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated immediately after diagnosis of acute HIV infection.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the state without ART).
Number of subjects: 22
Study: 34388324

Group type: EXPERIMENTAL
Intervention: HE4
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 445
Study: 34388386

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg per day; or 0.75 mg per day in patients with moderate renal impairment)
Number of subjects: 128
Study: 34388972

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) ß-1a, 3 doses of 125 μg by subcutaneous administration (days 1, 6, and 11)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) ß-1a
Number of subjects: 310
Study: 34389003

Group type: COMPARATOR
Intervention: Nesfatin-1 levels in CAD groups (UA & SCAD)
Number of subjects: 240

Group type: COMPARATOR
Intervention: DPP4 levels in CAD groups (UA & SCAD)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with hsCRP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with HOMA-IR
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with hyperlipidemia
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: DPP4 correlation with hs-CRP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: DPP4 correlation with FPG
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with severity of CAD (Gensini score)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: DPP4 association with severity of CAD
Number of subjects: 240
Study: 34389009

Group type: EXPERIMENTAL
Intervention: Wireless ultrasound-guided central venous catheter insertion (CVC)
Number of subjects: 30
Study: 34389161

Group type: EXPERIMENTAL
Intervention: Various treatment strategies attempted over the years for G6PD deficiency
Number of subjects: 400000000

Group type: EXPERIMENTAL
Intervention: Potential pharmacological pathways including glutathione (GSH) metabolism and compensatory NADPH production routes
Number of subjects: 400000000

Group type: EXPERIMENTAL
Intervention: Transcriptional upregulation of the G6PD gene
Number of subjects: 400000000
Study: 34389234

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4300

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 4300
Study: 34389237

Group type: EXPERIMENTAL
Intervention: Novel osimertinib combination therapies (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-biomarker selected therapies (chemotherapy- or EGFR-TKI-based) (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local practice treatment (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall study endpoints
Number of subjects: 0
Study: 34389504

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy for peanut allergy
Number of subjects: 0
Study: 34389568

Group type: EXPERIMENTAL
Intervention: Metabolic bariatric surgery (MBS), specifically vertical sleeve gastrectomy (VSG), details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical treatment approaches including lifestyle change, metformin, thiazolidinediones, or insulin, details on dosage and duration not available.
Number of subjects: 0
Study: 34389610

Group type: EXPERIMENTAL
Intervention: Intramuscular plasmid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of plasmid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified plasmid (for first-in-human studies)
Number of subjects: 0
Study: 34389618

Group type: EXPERIMENTAL
Intervention: GWN323 (1500 mg every 3 weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: GWN323 (750 mg) + spartalizumab (300 mg every 3 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: GWN323 (single-agent)
Number of subjects: 92

Group type: COMPARATOR
Intervention: GWN323 + spartalizumab (combination)
Number of subjects: 92
Study: 34389656

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in ex-smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in never-smokers
Number of subjects: 0
Study: 34389694

Group type: EXPERIMENTAL
Intervention: Tolinapant (ASTX660)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolinapant (ASTX660) + FOLFOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU)-based adjuvant chemotherapy
Number of subjects: 0
Study: 34389923

Group type: EXPERIMENTAL
Intervention: Culturally grounded physical activity intervention (hula lessons and self-regulation classes) for 12 months
Number of subjects: 263

Group type: COMPARATOR
Intervention: Education-only waitlist control group
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Culturally grounded physical activity intervention
Number of subjects: 263
Study: 34389930

Group type: EXPERIMENTAL
Intervention: Insulin pumps
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 2623

Group type: COMPARATOR
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 2623

Group type: COMPARATOR
Intervention: Self-Measured Blood Glucose (SMBG)
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Patch pump
Number of subjects: 2623

Group type: COMPARATOR
Intervention: Insulin pumps and CGM
Number of subjects: 2623
Study: 34390050

Group type: EXPERIMENTAL
Intervention: Increased heart rate (HR) during task performance
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Decreased heart rate variability (HRV) during task performance
Number of subjects: 51
Study: 34390338

Group type: EXPERIMENTAL
Intervention: DR9/DR9 genotype
Number of subjects: 237

Group type: COMPARATOR
Intervention: Non-DR9/DR9 carriers
Number of subjects: 237
Study: 34390394

Group type: EXPERIMENTAL
Intervention: Children and adolescents with SM
Number of subjects: 28

Group type: COMPARATOR
Intervention: Controls without SM
Number of subjects: 28
Study: 34390869

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene replacement therapy administered intravitreally in a phase I/IIa trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene replacement therapy
Number of subjects: 0
Study: 34391035

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: SARS-CoV-2 negative patients
Number of subjects: 62
Study: 34391384

Group type: EXPERIMENTAL
Intervention: Criteria-based rehabilitation program including strength and reactive strength targets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Previously successful rehabilitation program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Criteria-based rehabilitation program
Number of subjects: 60
Study: 34391393

Group type: EXPERIMENTAL
Intervention: Cannabidiol 600 mg (300 mg BID)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Risperidone 4 mg (2 mg BID)
Number of subjects: 130
Study: 34391399

Group type: EXPERIMENTAL
Intervention: Higher TGIF expression levels
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Higher TGIF expression levels in ER-positive BC patients
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Higher TGIF expression levels in HER2-negative subgroup
Number of subjects: 1197
Study: 34391408

Group type: COMPARATOR
Intervention: No dementia (MMSE 28-30)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MMSE 25-27)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mild dementia (MMSE 18-24)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Moderate dementia (MMSE 10-17)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Severe dementia (MMSE < 10)
Number of subjects: 137
Study: 34391480

Group type: EXPERIMENTAL
Intervention: BI 187004 (2.5-360 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BI 187004 (5 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BI 187004 (160 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BI 187004 (10 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BI 187004 (360 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 34391745

Group type: EXPERIMENTAL
Intervention: Peak Oxygen Uptake (pVO2) measurement after LVAD implantation
Number of subjects: 450
Study: 34391791

Group type: EXPERIMENTAL
Intervention: Single high-sensitive cardiac troponin I (hs-cTnI) measurement at admission, diagnostic cut-off <3 ng/L
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Single hs-cTnI measurement at admission
Number of subjects: 1370
Study: 34391922

Group type: EXPERIMENTAL
Intervention: mt-HBT
Number of subjects: 136

Group type: COMPARATOR
Intervention: AFP (20 ng/mL or greater)
Number of subjects: 136

Group type: COMPARATOR
Intervention: GALAD (-0.63 or greater)
Number of subjects: 136
Study: 34392187

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 20
Study: 34392257

Group type: EXPERIMENTAL
Intervention: CRT responders without VT/VF occurrence
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: CRT nonresponder patients who suffered VT/VF
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: CRT nonresponder patients without VT/VF occurrence
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: CRT responders
Number of subjects: 1308
Study: 34392310

Group type: EXPERIMENTAL
Intervention: Serum DHA levels during the first 28 postnatal days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum AA levels during the first 28 postnatal days
Number of subjects: 90
Study: 34392333

Group type: EXPERIMENTAL
Intervention: GORE thoracic aortic devices for DTAA repair
Number of subjects: 310
Study: 34392453

Group type: EXPERIMENTAL
Intervention: GT0918 (500 mg QD)
Number of subjects: 18
Study: 34392637

Group type: EXPERIMENTAL
Intervention: Double hydrashift assay
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MS-MRD assay
Number of subjects: 3
Study: 34392819

Group type: EXPERIMENTAL
Intervention: Maternal CMV seroprevalence
Number of subjects: 6729

Group type: EXPERIMENTAL
Intervention: Congenital CMV (cCMV) prevalence
Number of subjects: 6729

Group type: EXPERIMENTAL
Intervention: cCMV infection in newborns from seropositive mothers
Number of subjects: 6729

Group type: EXPERIMENTAL
Intervention: cCMV infection in newborns from seronegative mothers
Number of subjects: 6729
Study: 34393061

Group type: EXPERIMENTAL
Intervention: Lenvatinib and Pembrolizumab
Number of subjects: 43
Study: 34393139

Group type: EXPERIMENTAL
Intervention: with-COVID-19 group (132 patients)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: with-COVID-19 group (subgroups)
Number of subjects: 265

Group type: COMPARATOR
Intervention: pre-COVID-19 group (133 patients)
Number of subjects: 265
Study: 34393192

Group type: EXPERIMENTAL
Intervention: Latent class analysis based on the Edmonton Symptom Assessment System measuring nine symptoms on a scale of 0-10.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Membership in the high symptom burden latent subgroup.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults between 65 and 74 years.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High symptom burden.
Number of subjects: 0
Study: 34393199

Group type: EXPERIMENTAL
Intervention: Multivariable prediction model for persistent NSDs
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Factors associated with neurosensory recovery
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Pain intensity and QoL analysis
Number of subjects: 384